Company overview
Pliant Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases. The company's lead candidate includes bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which has completed phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325, a phase 1-ready program for treatment of the muscular dystrophies, including duchenne muscular dystrophy. Pliant Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Daily valuation snapshot
These values come from the daily market snapshot dated 2026-10-08. TTM means trailing twelve months. Use the market date when comparing PLRX with another company.
| Daily close (USD) | $1 |
| Market capitalization (USD) | $61,921,897 |
| Price / earnings (TTM) | Not reported |
| Price / book | 0.42 |
No matching rows. Clear the filter to see all records.
Read PLRX's valuation metrics
Company size
Pliant Therapeutics, Inc. Common Stock's recorded market capitalization is $61,921,897. It measures the market value of the company's equity, rather than its revenue or cash balance.
Price relative to earnings
P/E compares share price with trailing annual earnings per share. For a company with losses, inspect the earnings figures directly rather than treating a negative multiple as a cheap valuation.
Price relative to book equity
PLRX's recorded price-to-book ratio is 0.42. That compares its market equity value with recorded book equity. Examine its business and balance sheet to understand why those values differ.
Research Pliant Therapeutics, Inc. Common Stock with Aurora
Use the snapshot above to ask a specific question about PLRX. Ask for the report period and the figures behind the explanation, then compare the answer with the company's business description.
Continue the research
Follow PLRX's ownership disclosures to see who filed a transaction or position and when it became public. To turn a research idea into a strategy, define an entry rule and test its dated observations.